Fosun Pharma (600196.SH; 02196.HK) released its Q1 2026 financial results on April 28, 2026. The following is a summary of the quarterly report:
Financial Highlights (Q1 2026)
- Revenue: RMB 10.073 billion, a year-on-year increase of 6.93% (approximately 8.58% growth at constant exchange rates, excluding the impact of RMB appreciation). This marks the first time the company’s quarterly revenue has surpassed the RMB 10 billion milestone.
- Net Profit Attributable to Shareholders: RMB 871 million, a year-on-year increase of 13.87%.
- Net Profit After Deducting Non-recurring Items: RMB 501 million, a year-on-year increase of 21.96%, indicating an improvement in core business profitability.
- Net Cash Flow from Operating Activities: RMB 1.149 billion, a year-on-year increase of 8.80%.
- R&D Expenditure: RMB 897 million, an increase of RMB 159 million year-on-year.
Business and Strategic Progress
- Innovation Pipeline Advancement:
- During the reporting period, New Drug Applications (NDA) for 4 innovative drugs were accepted by the NMPA or the US FDA.
- 14 clinical trials for innovative drugs were approved by regulatory authorities domestically and internationally.
- Fosun Pharma was ranked among the top 20 global pharmaceutical R&D companies in the “2026 Annual Review of Pharmaceutical R&D” white paper.
- Key Technical Progress:
- The Denosumab injection (HLX14) developed by its subsidiary, Henlius, was approved for marketing in Canada in March 2026.
- The self-developed MEK 1/2 inhibitor, Ruwometinib tablets (Fu Mai Ning), has entered priority review.
- The marketing application for the Class 1 new drug, Furetinib succinate capsules (SAF-189), has been accepted.
- AI Strategic Layout: The company continues to advance its “Full Embrace of AI” strategy, establishing a digital and intelligent architecture to deeply integrate AI into decision-making across the full lifecycle, including drug discovery, clinical research, and product management.
Financial Information Source
For detailed data, please refer to the official announcement by Fosun Pharma: Q1 2026 Report (PDF)
Fosun Pharma (600196.SH; 02196.HK)’s Q1 2026 financial report indicates that the company is currently in a harvest period characterized by innovation transformation and global expansion. Below is the summary:
Key Developments in Q1
- Revenue Milestone: Quarterly revenue reached RMB 10.073 billion, hitting a record high with a year-on-year increase of 6.93%.
- Improved Profitability: Net profit after deducting non-recurring items grew by 21.96% year-on-year, significantly outpacing revenue growth, demonstrating enhanced core business profitability and effective cost control.
- Innovation Commercialization: R&D investment remained high (RMB 897 million), with multiple innovative drugs entering the harvest phase (4 NDAs accepted, 14 clinical trials approved).
- International Breakthrough: The Denosumab injection (HLX14) developed by the subsidiary, Henlius, was approved for marketing in Canada in March, marking an improvement in the commercialization capabilities of its biosimilars in mature markets.
Outlook
- Strategic Direction: Continue to deepen the three core strategies: “Innovation-led,” “Deep Globalization,” and “Full Embrace of AI.”
- R&D Driven: Expected to further accelerate pipeline conversion, particularly in antibody/ADC technology platforms and oncology. With multiple drugs entering priority review or late-stage clinical trials, commercial value will be released gradually.
- Digital Transformation: Further implement the PharmAID® AI platform to optimize performance across the entire lifecycle, from R&D decision-making to clinical trials, aimed at reducing R&D costs and increasing success rates.
EPS Forecast for the Coming Year
Based on market analyst estimates, as the innovative drug product line matures and global market access expands, the earnings expectations for Fosun Pharma are as follows:
| Forecast Year | EPS Forecast (RMB) |
| 2026 (Current Year) | Approx. 1.50 |
| 2027 (Coming Year) | Approx. 1.70 |
Note: EPS forecasts are based on public market analyst estimates. Actual figures may vary due to R&D progress, market competition, and macroeconomic conditions. Please consider the company’s financial reports and announcements for investment decisions.
Sources:
Fosun Pharma (2196.HK) Growth Engine Driven by Innovative Drugs and Global Strategy – HK01
Back to Fosun Pharma